Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
6825946 | Schizophrenia Research | 2013 | 8 Pages |
Abstract
Comparison of methods for calculating antipsychotic dose equivalence suggests that different methods yield different equivalencies and the evidence is not sufficiently robust for any of these to be considered as a gold standard method. Thus, choice of method may introduce bias, either an over or underestimate of equivalent dosage, when designing head-to-head, antipsychotic, fixed-dose trials. Consequently, clinical trial reports should routinely include justification of the choice of method for calculating dose equivalence.
Related Topics
Life Sciences
Neuroscience
Behavioral Neuroscience
Authors
Maxine X. Patel, Ioli A. Arista, Mark Taylor, Thomas R.E. Barnes,